Cochrane Review: Lactulose versus Polyethylene Glycol for Chronic Constipation

Department of General Surgery, Northern General Hospital, Herries Road, Sheffield, England, UK, S5 7AU.
Cochrane database of systematic reviews (Online) (Impact Factor: 6.03). 07/2010; 6(7):CD007570. DOI: 10.1002/14651858.CD007570.pub2
Source: PubMed


Constipation is a common clinical problem. Lactulose and Polyethylene Glycol (PEG) are both commonly used osmotic laxatives that have been shown to be effective and safe treatments for chronic constipation. However, there is no definitive data as to which provides the best treatment.
To identify and review all relevant data in order to determine whether Lactulose or Polyethylene Glycol is more effective at treating chronic constipation and faecal impaction.
We searched the MEDLINE, EMBASE and CINAHL databases, and the Cochrane Central Register of Controlled Trials for all randomised controlled trials (RCTs) comparing the use of lactulose and polyethylene glycol in the management of faecal impaction and chronic constipation.
Studies were included if they were randomised controlled trials which compared lactulose with polyethylene glycol in the management of chronic constipation.
Data on study methods, participants, interventions used and outcomes measured was extracted from each study. Data was entered into the Cochrane Review Manager software (RevMan 5.0) and analysed using Cochrane MetaView.
In the present meta-analysis, we considered for the first time all ten randomised controlled trials so far performed. The findings of our work indicate that Polyethylene glycol is better than lactulose in outcomes of stool frequency per week, form of stool, relief of abdominal pain and the need for additional products. On subgroup analysis, this is seen in both adults and children, except for relief of abdominal pain.
Polyethylene Glycol should be used in preference to Lactulose in the treatment of Chronic Constipation.

Download full-text


Available from: Jenna Morgan, Oct 02, 2015
220 Reads
  • Source
    • "This suggests the potential for a "carry-over" effect with lactulose; it would be interesting to explore whether this arises from a prebiotic effect. Lactulose treatment may be associated with cramps, bloating and flatulence.59 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic constipation (CC) may impact on quality of life. There is substantial patient dissatisfaction; possible reasons are failure to recognize underlying constipation, inappropriate dietary advice and inadequate treatment. The aim of these practical guidelines intended for primary care physicians, and which are based on Asian perspectives, is to provide an approach to CC that is relevant to the existing health-care infrastructure. Physicians should not rely on infrequent bowel movements to diagnose CC as many patients have one or more bowel movement a day. More commonly, patients present with hard stool, straining, incomplete feeling, bloating and other dyspeptic symptoms. Physicians should consider CC in these situations and when patients are found to use laxative containing supplements. In the absence of alarm features physicians may start with a 2-4 week therapeutic trial of available pharmacological agents including osmotic, stimulant and enterokinetic agents. Where safe to do so, physicians should consider regular (as opposed to on demand dosing), combination treatment and continuous treatment for at least 4 weeks. If patients do not achieve satisfactory response, they should be referred to tertiary centers for physiological evaluation of colonic transit and pelvic floor function. Surgical referral is a last resort, which should be considered only after a thorough physiological and psychological evaluation.
    Journal of neurogastroenterology and motility 04/2013; 19(2):149-60. DOI:10.5056/jnm.2013.19.2.149 · 2.30 Impact Factor
  • Source
    • "In the pediatric population, the prevalence of constipation seems to have increased over time [9, 13]. However, this might be a false image, because the use of laxatives was a key component in establishing constipation in both reports, and laxatives probably are prescribed more readily now in CF patients suspected of constipation, especially because current laxatives are almost devoid of side effects [15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Meconium ileus at birth, distal intestinal obstruction syndrome (DIOS), and constipation are an interrelated group of intestinal obstruction syndromes with a variable severity of obstruction that occurs in cystic fibrosis patients. Long-term follow-up studies show that today meconium ileus is not a risk factor for impaired nutritional status, pulmonary function, or survival. DIOS and constipation are frequently seen in cystic fibrosis patients, especially later in life; genetic, dietary, and other associations have been explored. Diagnosis of DIOS is based on suggestive symptoms, with a right lower quadrant mass confirmed on abdominal radiography, whereas symptoms of constipation are milder and of longer standing. In DIOS, early aggressive laxative treatment with oral laxatives (polyethylene glycol) or intestinal lavage with balanced osmotic electrolyte solution and rehydration is required, which now makes the need for surgical interventions rare. Constipation can generally be well controlled with polyethylene glycol maintenance treatment.
    Current Gastroenterology Reports 03/2011; 13(3):265-70. DOI:10.1007/s11894-011-0185-9
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this article, traditional and novel therapies for chronic constipation are reviewed. Traditional laxatives are effective at inducing bowel movements, but efficacy in long-term management and efficacy on constipation-associated abdominal symptoms are less well established, with the exception of polyethylene glycol, for which long-term studies confirm sustained efficacy. Recently approved drugs include the colonic secretagogue lubiprostone and the 5-HT4 agonist prucalopride. In controlled trials in chronic constipation, these drugs were shown to significantly improve constipation and its associated symptoms, with a favourable safety record. Methylnaltrexone, a subcutaneously administered peripherally acting mu opioid receptor antagonist, has recently been approved for opioid-induced constipation in terminally ill patients. New agents under evaluation include the 5-HT4 agonists velusetrag and naronapride, the guanylate cyclase-C receptor agonist linaclotide and the peripherally acting mu opioid receptor antagonist alvimopan.
    Best practice & research. Clinical gastroenterology 02/2011; 25(1):151-8. DOI:10.1016/j.bpg.2011.01.005 · 3.48 Impact Factor
Show more